SARS‐CoV‐2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens

DOI Web Site Web Site Web Site 被引用文献4件
  • Liang Peng
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Jing Liu
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Wenxiong Xu
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Qiumin Luo
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Dabiao Chen
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Ziying Lei
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Zhanlian Huang
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Xuejun Li
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Keji Deng
    Jinan University Guangzhou China
  • Bingliang Lin
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
  • Zhiliang Gao
    Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Purpose</jats:title><jats:p>The purpose of this study was to detect severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) ribonucleic acid (RNA) in urine and blood specimens, and anal and oropharyngeal swabs from patients with confirmed SARS‐CoV‐2 infection, and correlated positive results with clinical findings.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients with confirmed SARS‐CoV‐2 infections were included in this study. Patients' demographic and clinical data were recorded. Quantitative real‐time polymerase chain reaction was used to detect SARS‐CoV‐2 RNA in urine and blood specimens, and anal and oropharyngeal swabs. The study is registered at <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</jats:ext-link> (No. NCT04279782, 19 February, 2020).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>SARS‐CoV‐2 RNA was present in all four specimen types, though not all specimen types were positive simultaneously. The presence of viral RNA was not necessarily predictive of clinical symptoms, for example, the presence of viral RNA in the urine did not necessarily predict urinary tract symptoms.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>SARS‐CoV‐2 can infect multiple systems, including the urinary tract. Testing different specimen types may be useful for monitoring disease changes and progression, and for establishing a prognosis.</jats:p></jats:sec>

収録刊行物

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ